Peter Greenleaf serves as the Chief Executive Officer at Aurinia Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing therapies to treat autoimmune, kidney, and rare diseases. With a robust background in the pharmaceutical industry, Greenleaf has held numerous leadership positions that have prepared him for his current role at Aurinia. Before joining Aurinia in 2019, he was the CEO of Sucampo Pharmaceuticals, where he successfully led the company through its acquisition by Mallinckrodt. Prior to Sucampo, Greenleaf served as President and CEO of Histogenics Corporation and held various executive positions at MedImmune, LLC, a subsidiary of AstraZeneca. At Aurinia, Greenleaf has been instrumental in steering the company through significant milestones, including the successful launch of Lupkynis, the first FDA-approved oral therapy for lupus nephritis. Under his leadership, Aurinia has expanded its research and development efforts, aiming to bring new treatments to patients with unmet medical needs. Greenleaf's strategic vision and deep industry knowledge have been pivotal in positioning Aurinia as a leader in the biopharmaceutical space. His commitment to innovation and patient care continues to drive the company's growth and success. In addition to his corporate achievements, Peter Greenleaf is known for his dedication to advancing the biopharmaceutical industry through thought leadership and advocacy. He frequently speaks at industry conferences and participates in initiatives aimed at improving healthcare outcomes. Greenleaf holds a Bachelor of Science in Business from the University of Colorado and has completed executive education programs at Stanford University and Harvard Business School. His blend of scientific understanding and business acumen makes him a respected figure in the industry, and his leadership at Aurinia continues to inspire both his team and the broader healthcare community.